ClinicalTrials.gg

Program

GSK4425689A

A development code. Also written as “GSK4425689A SC” and “GSK4425689A IV”.

In GlaxoSmithKline's pipeline, Circumsporozoite protein inhibitor. Its studies are mostly in Malaria, Falciparum, led by GlaxoSmithKline.

Furthest: phase 1, since Jun 9, 20261 company-led study, 1 open or runningNext primary completion: Apr 10, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Jun 9, 2026Jun 9, 2026Apr 10, 2028phase 1 · NCT07646353
  • Named in GlaxoSmithKline’s own pipeline as GSK4425689, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2026First study: phase 1 study in Malaria, FalciparumFirst studyNCT07646353 · 40 planned · United Kingdom

Ahead

  1. Apr 10, 2028Primary completion: phase 1 study in Malaria, FalciparumNCT07646353

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Circumsporozoite protein inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07646353Malaria, Falciparum · United Kingdom1RecruitingApr 10, 202840

How it is read

Names in the registry

  • “GSK4425689A SC”, 1 entry
  • “GSK4425689A IV”, 1 entry

Codes read as this program: GSK4425689A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.